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Resumo  
 
A deposição do péptido β-amilóide (Aβ), no cérebro de pacientes com Doença de Alzheimer (DA), tem 
sido implicada na progressiva morte neuronal por apoptose verificada nesta patologia.  
O lítio é um fármaco que se tem revelado neuroprotector na toxicidade induzida pelo péptido Aβ. Por 
outro lado, este fármaco é conhecido como sendo um indutor dum mecanismo de sobrevivência celular 
designado autofagia, assim como, potenciador da sinalização do factor neurotrófico derivado do cérebro (Brain-
derived neurotrophic factor-BDNF).  
O BDNF promove a sobrevivência neuronal pela activação dos receptores TrkB-Full lenght (FL) mas, pode 
também activar os receptores TrkB-Truncado (Tc) que funcionam como moduladores negativos dos primeiros. 
Assim, alterações na proporção entre estes receptores podem estar envolvidas em variações da função do BDNF. 
No cérebro de pacientes com AD observa-se uma redução dos receptores TrkB-FL e um aumento dos Tc. 
Dados do laboratório demonstraram que estas alterações poderão ser resultado da deposição do péptido Aβ. 
Assim, este projecto teve como objectivo estudar o papel neuroprotector do lítio na apoptose induzida 
pelo Aβ25-35 em culturas neuronais e, investigar se os mecanismos envolvidos poderiam estar relacionados com a 
modulação dos níveis de receptores TrkB e/ou com a sua capacidade de induzir autofagia.  
Os resultados mostraram que a incubação de culturas de neurónios primários com LiCl ou com o seu 
controlo salino, NaCl, reduziu os níveis e a actividade do marcador de apoptose, caspase-3, induzido pelo Aβ. 
Verificou-se ainda que, as alterações induzidas pelo Aβ na proporção entre as isoformas do receptor TrkB são 
prevenidas tanto pelo LiCl como pelo NaCl, sugerindo que a redução da apoptose possa estar relacionada com 
estas modificações. Finalmente, um inibidor da autofagia, não preveniu o efeito neuroprotector do LiCl, 
sugerindo que a autofagia pode não estar envolvida neste efeito.  
Em conclusão, este trabalho revelou que o LiCl previne a apoptose e as alterações dos níveis dos 
receptores TrkB, induzidas pelo Aβ. No entanto, curiosamente, também o NaCl, usado como controlo salino, 
demonstrou ter efeitos similares. Assim, este trabalho sugere que muitos dos efeitos neuroprotectores 
associados ao Lítio poderão estar relacionados com alterações iónicas.  
 
 
Palavras-chave:  Lítio, neuroprotecção, péptido β-amilóide, apoptose, BDNF, receptores TrkB, culturas 
neuronais.  
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Abstract  
 
The deposition of amyloid-β (Aβ) peptide, in the brain of patients with Alzheimer’s disease (AD), has 
been implicated in the progressive neuronal death by apoptosis observed in this pathology. 
It has been demonstrated that lithium is neuroprotector against Aβ peptide toxicity. This drug is known 
as an inducer of a mechanism of cell survival named autophagy, as well as an enhancer of Brain-derived 
neurotrophic factor (BDNF) signaling. 
BDNF promotes neuronal survival by activating TrkB-Full length (FL) receptors. However this 
neurotrophin also activates TrkB-Truncated (Tc) receptors which act as negative modulators of TrkB-FL. 
Therefore, changes in the proportion between these receptors might be associated with changes in BDNF 
functions.  
In the brain of AD patients, a decrease in TrkB-FL receptors and an increase of TrkB-Tc is observed. Data 
obtained in the host laboratory showed that these changes might be a result of Aβ peptide deposition.     
Thus, this project aimed to study the role of lithium on apoptosis induced by Aβ25-35 peptide, in neuronal 
cultures, and investigate whether the mechanisms underlying this possible neuroprotective effect of lithium 
could be related with the modulation of TrkB receptor levels and/or its ability of inducing autophagy.  
The results showed that incubation of primary neuronal cultures with LiCl or with its saline control, NaCl, 
reduced both levels and activity of an apoptotic marker, caspase-3, induced by Aβ peptide. It was also shown 
that changes, induced by Aβ peptide, in the proportion between the two isoforms of TrkB receptors were 
prevented either by LiCl or NaCl, suggesting that the reduction on apoptosis might be related with these changes. 
Finally, an inhibitor of autophagy was not able to prevent lithium’s neuroprotective effect, suggesting that 
autophagy might not be involved in this effect. 
In conclusion, this experimental work showed that LiCl prevents apoptosis and changes in the levels of 
TrkB receptors, induced by Aβ peptide. However, curiously, similar results were obtained upon incubation of 
neuronal cultures with NaCl, used as a saline control. Therefore, this work suggests that many of the 
neuroprotective effects associated with lithium might be related with ionic changes.   
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1| Introduction 
 
1.1 – Alzheimer’s disease  
 
Alzheimer's disease (AD) is the most prevalent neurodegenerative pathology in humans (Gold and 
Budson, 2008).  
This disorder involves a progressive cortical atrophy and neuronal loss that leads to a profound 
impairment of memory and decline of other intellectual functions (Yanker et al, 1996).   
In the brain of AD patients two hallmark neuropathological lesions are present: the intracellular 
neurofibrillary tangles, consisting of hyperphosphorylated forms of microtubule-associated (Tau) protein, and 
senile plaques (Yanker et al, 1996). The senile plaques are extracellular clusters mainly constituted by amyloid-β 
(Aβ) peptide, constituted by a peptide with 40-42 amino acid, generated from β- and γ-secretase cleavage of the 
Aβ precursor protein (APP; Figure 1; Glenner and Wong, 1984 ; Cupers et al, 2001), but also by Aβ25-35 oligomers 
(Gruden et al, 2007; Kubo et al, 2002).   
Aβ peptide is secreted constitutively by cells in culture and detected as a circulating peptide in the 
plasma and cerebrospinal fluid (CSF) of healthy humans and other mammals. However, the composition of the 
Aβ peptides present in culture medium, human CSF or in the amyloid deposits observed in the brain of AD 
subjects is very heterogeneous in both their amino- and carboxyl-terminal regions. The C-terminal heterogeneity 
of Aβ has special importance for its aggregation (reviewed in Selkoe, 1999). 
 
 
Figure 1 - Proteolysis of APP. APP is a type 1 transmembrane 
protein in which the carboxyl-terminal portion of Aβ peptide is 
embedded within the cell membrane.  
APP undergoes two endoproteolytic cleavage events 
that either preclude or cause the formation of the amyloidogenic 
Aβ peptide, i.e., peptides with the ability to spontaneously self-
assemble, forming aggregates. Cleavage by α-secretase — a 
membrane-associated metalloproteinase — occurs within the Aβ 
domain, precluding the liberation of amyloidogenic species, and 
resulting in the release of the large soluble extracellular amino-
terminal portion of APP (APPsα) and a carboxy-terminal fragment. 
To release the Aβ species, APP must undergo two sequential 
endoproteolytic steps that are mediated by distinct enzymatic activities known as β- and γ-secretase. β-secretase cleaves APP 
at the amino-terminal region of the Aβ sequence, generating a slightly shorter soluble amino terminus (APPsβ) and the 
amyloidogenic carboxy-terminal fragment (C99). Cleavage of C99 by γ-secretase liberates the carboxy-terminal 50 residues of 
APP, known as the APP intracellular domain (AICD). This is then followed by cleavage of the Aβ-containing fragment at the γ-
secretase site after residue 40 or 42 of Aβ (adapted from LaFerla, 2002). 
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1.2 – Neurotoxicity of Amyloid-β peptide 
 
There are evidences that accumulation of Aβ peptide, the main component of the senile plaques, can 
result in oxidative stress, inflammation, and neurotoxicity, which in turn initiates a pathogenic cascade, 
ultimately leading to apoptosis and deterioration of synaptic transmission (Yanker et al, 1996). For these reasons, 
Aβ peptide deposits in the brain have been considered a potential cause for the progressive neuronal loss 
observed in AD patients (Shimohama, 2000). Supporting the idea that Aβ peptides may facilitate 
neurodegeneration is the fact that senile plaques are typically surrounded by dystrophic neuritis (Tanzi et al, 
1989; Selkoe, 1991, Figure 2). 
 
 
 
 
 
Figure 2 – Stained histologic view of a senile plaque, where Aβ deposits (dark center) 
surrounded by degenerating dendrites and axons are visible (adapted from Maccioni et al, 2001).  
 
 
Neurotoxicitiy induced by Aβ peptides is related to their state of aggregation. In 1993, Pike and 
collaborators reported that only Aβ peptides containing the hydrophobic β29-35 sequence are predicted to form 
assemblies, and only these peptides, exhibiting stable aggregates, are neurotoxic. In addition, it was also 
demonstrated that a reduction of aggregation is accompanied by corresponding reduction in toxicity (Pike et al, 
1993). Aβ25-35 peptide contains this hydrophobic sequence and, consequently it retains the ability of self-
aggregation as insoluble fibrils (Yanker et al, 1990) and the toxic effect of larger Aβ peptides (Maurice et al, 1996; 
Meunier et al, 2006; Pike et al, 1993). Inclusively, it was shown that this peptide is even more toxic in cortical 
neurons, than the Aβ1-42 peptide (Arancibia, 2008). 
Several studies have shown that in human tissue of AD brains (Anderson et al, 1996; Stadelmann et al, 
1999) and in primary cultures of rat cortical neurons (Estus et al, 1997) exposed to Aβ peptide, the dying cells 
display the characteristics of apoptosis. 
The mechanisms underlying apoptosis induced by Aβ peptides are not fully understood. Nevertheless, 
there are several mechanisms suggested to be involved in its toxicity (Figure 3), including an increase of Tau 
phosphorylation (Alvarez et al, 1999; Busciglio et al, 1995; Ferreira et al, 1998; Takashima et al, 1998); activation 
of c-Jun N-terminal Kinase (JNK) pathway (Morishima et al, 2001); downregulation of brain-derived neurotrophic 
factor (BDNF) functions (Tong et al, 2004), as well as, mitochondrial dysfunction (Casley et al, 2002) and 
perturbation of intracellular calcium homeostasis (reviewed in LaFerla, 2002), among others.  
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Figure 3 – Actions of Aβ peptide and possible mechanisms underlying its neurotoxicity. The mechanisms through which Aβ 
peptide triggers apoptosis are not completely clarified yet. Currently, several actions of Aβ peptide are suggested to 
contribute to its neurotoxicity: 1) administration of Aβ peptide has been correlated with the increase in phosphorylation of 
Tau protein (Alvarez et al, 1999; Busciglio et al, 1995; Ferreira et al, 1998; Takashima et al, 1998); 2) Aβ peptide activates the 
JNK pathway, which can culminate in an increase of FasL and activation of the extrinsic apoptotic signalling pathway 
(Morishima et al, 2001; Nagata et al, 1997); 3) Aβ peptide at sublethal concentration (200µM) interferes with BDNF-induced 
activation of PI3K and MAPK pathways (Tong et al, 2004), which are crucial for neuronal survival; 4) the redox potential of 
mitochondria can be affected by Aβ peptide, leading to the production of free radicals (Yanker, 1996; Casley et al, 2002 ) 
and 5) Aβ peptide can increase the levels of intracellular calcium (reviewed in LaFerla, 2002).   
 
 
1.3 – Treatment of Alzheimer’s disease  
 
Currently, there is no cure for AD. However, several drugs are being used to minimize some of the 
symptoms observed in this neurodegenerative disorder.  
One of the features that has been frequently reported in AD is the reduction in the activity of cholinergic 
neurons (Rossor, 1982).  To balance this situation, inhibitors of acetylcholinesterase, which block the activity of 
the enzyme responsible for the cleavage of acetylcholine on the synaptic cleft, are being used in AD’s treatment. 
These drugs, by inhibiting acetylcholine degradation, counteract the degeneration of cholinergic neurons. An 
antagonist of glutamate NMDA receptor, memantine, is also used as a treatment for this pathology; since it has 
been reported that glutamate excitoxicity in AD occurs as a possible consequence of an abnormal release of this 
neurotransmitter and overstimulation of its receptors. By blocking NMDA receptors, memantine avoids 
glutamate excitoxicity that can be responsible for neuronal cell death (Reisberg, 2003). 
As previously mentioned, these drugs do not cure Alzheimer’s disease; they just attempt to minimize 
some symptoms of the pathology. Consequently, discover and study of new molecules to treat or ameliorate this 
disease is urgent.   
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1.4 – Lithium in Alzheimer’s disease treatment 
 
Recently the possibility of using lithium in AD prevention has emerged (Yeh and Tsai, 2008).  
Lithium is an effective mood stabilizer used, for decades, in the prevention and in acute treatment of 
bipolar disorders. The molecular mechanisms underlying the actions of this drug and illness itself are not 
completely understood, however inositol depletion has been proposed as the most probable mechanism of 
action for lithium (Williams et al, 2002). 
The possibility of using lithium to prevent AD emerged from the knowledge that lithium is involved in 
many processes implicated in this disorder: it decreases the calcium influx mediated by glutamate (Shao et al, 
2005); it inhibits GSK-3, an enzyme that, when overexpressed, induces aggregation of Tau protein into tangles 
(Jackson et al, 2002) and induces autophagy, a cell survival mechanism, by inhibiting inositol monophosphatase 
(IMPase; Sarkar et al, 2005). Moreover, it was also reported that lithium prevents toxicity induced by a variety of 
insults (Chuang et al, 2002). It increases cell viability and protects cultured neurons (Alvarez et al, 1999), rat 
pheochromocytoma (PC12) cells and cerebellar granule cell neurons (Wei et al, 2000) against Aβ peptide toxicity; 
and also protects cerebellar granule cell neurons from glutamate toxicity (Nonaka et al, 1998). 
In 2001, Fukumoto and collaborators showed that, in the rat brain, chronic lithium treatment increases 
the expression of BDNF (Fukumoto et al, 2001) which is neuroprotective against toxic effects of Aβ peptides 
(Arancibia, 2008). In addition, a clinical study reported that the prevalence of AD is lower in patients on a chronic 
lithium treatment (Nunes et al, 2007). 
 
 
1.5 – BDNF and its receptors 
 
BDNF is a member of the neurotrophin family. Neurotrophins play a prominent role in neuronal 
development, growth, and plasticity in the vertebrate nervous system (Huang, 2001; Chao, 2003). 
The actions of neurotrophins are mediated by two classes of cell surface receptors: tropomyosin-related 
kinase (Trk) family of tyrosine kinase receptors and the p75 neurotrophin receptor (p75
NTR
), a member of the 
tumour necrosis factor receptor superfamily (Chao, 1995). Although several neurotrophins are homologous in 
amino acid sequence and structure, they are very different in their affinity to the different subtypes of Trk 
receptors. For example, Nerve Growth Factor (NGF) binds exclusively to TrkA, whereas BDNF binds to TrkB 
receptor (Lewin and Bard, 1996).  
Figure 4 presents the different neurotrophin receptors and their ligands. 
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Figure 4 – Neurotrophin receptors, Trk and p75, and 
respective ligands (adapted from Chao, 2003). 
 
 
 
After binding to TrkB receptor, BDNF induces dimerization, kinase activation and autophosphorylation at 
multiple and specific tyrosine residues within the intracellular domains of TrkB receptors (reviewed in Segal and 
Greenberg, 1996). The phosphorylated tyrosines provide sites for interaction with adaptor proteins, as the Src 
homologous and collagen-like (Shc) and phospholipase C-γ (PLC-γ). The binding of these proteins to the activated 
TrkB receptor leads to the activation of three major signalling pathways: PI3K/Akt; Ras/MAPK and PLC-γ pathway 
(Figure 5; reviewed in Segal and Geenberg, 1996; Arévalo and Wu, 2006; Blum and Konnerth, 2005).  
 
 
 
Figure 5 – TrkB signalling. The binding of BDNF to TrkB 
receptor culminates in its activation and in the recruitment 
of different adaptor proteins, which leads to the 
subsequent activation of several intracellular signalling 
cascades.  TrkB receptors predominantly signal through the 
activation of PLCγ, Akt and MAPK pathways. 
Phosphorylation of the tyrosine at the position 515 (Y
515
) 
results in the activation of the PI3K/Akt signalling pathway 
through the recruitment of the adaptor protein, Shc 
(Patapoutian and Reichart, 2001) and formation of a 
complex with various proteins (Shc/Grb2/SOS). Shc also 
activates Ras, which mediates the activation of PI3K 
pathway and the mitogen-activated protein kinase 
(MAPK)/ERK pathway, crucial for cell survival and differentiation. On the other hand, phosphorylation of the tyrosine at the 
position 816 (Y
816
) will promote the recruitment of PLC-γ that results in the release of inositol phosphates and activation of 
protein kinase C (PKC) (adapted from Arévalo and Wu, 2006; Chao, 2003; Hashimoto; 2002). 
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1.6 – BDNF signalling in Alzheimer’s disease 
 
Changes in the signalling mediated by neurotrophins are often associated with neurodegenerative 
disorders (reviewed in Roux and Barker, 2002). 
Several investigations have reported that levels of BDNF are decreased in the brain of AD patients. In 
1997, Connor and collaborators reported that the levels of this neurotrophin are decreased in human post-
mortem AD hippocampus (Connor, 1997) and other studies also observed that the precursor and mature forms 
of BDNF (Peng et al, 2005; Michalski and Fahnestock, 2003) or its mRNAs (Holsinger et al, 2000; Phillips et al, 
1991) are decreased in the parietal cortex and hippocampus, even in pre-clinical stages of AD. BDNF serum 
concentrations also vary over the course of the disease and are correlated with the severity of dementia (Laske 
et al, 2007). 
TrkB receptors are also changed in AD. Studies performed in the frontal cortex and hippocampus of 
individuals affected by long-lasting severe AD showed that, in addition to decreased BDNF levels, the expression 
of the complete isoform of TrkB receptor, the TrkB-Full length (TrkB-FL), usually associated to neuronal survival, 
is also reduced. Moreover, it was shown that decreases in BDNF and TrkB-FL are accompanied by an increase in 
the expression of the TrkB-Truncated (TrkB-Tc) isoform (Ferrer et al, 1999).  
Besides these relevant findings, it was shown that exogenous administration of BDNF exerts 
neuroprotective actions against toxic effects of Aβ peptides in brain regions related to cognitive functions 
(Arancibia et al, 2008). Moreover, it was demonstrated that neurons containing neurofibrillary tangles, one of 
the hallmark lesions of Alzheimer’s, do not contain BDNF-immunoreactive material whereas most intensely 
BDNF-labelled neurons were devoid of tangles (Murer et al, 1999). 
Thus the data point toward an important role of BDNF in the etiology of AD. 
 
 
1.7 – Autophagy 
 
Autophagy is a process by which eukaryotic cells eliminate protein complexes and organelles, by acidic 
hydrolases, contained in lysosomes. These enzymes degrade superfluous and obsolete intracellular 
macromolecules and organelles, as well as those that are in excess. These substances are broken down into 
biologically active monomers that may be, subsequently, re-used to maintain cellular metabolism and 
homeostasis (Shintani and Klionsky, 2004).   
There are three forms of autophagy that differ in physiological function and role of lysosomes involved 
in the process:  microautophagy, chaperone-mediated autophagy and macroautophagy (Shintani and Klionsky, 
2004).  The last one is the best understood form of autophagy and entails the formation of an “isolation” 
membrane around the cytoplasmic regions and organelles intended for degradation, forming double membrane-
limited structures, called autophagosomes. Subsequently, these fuse with lysosomes, forming single membrane 
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autophagolysosomes or autolysosomes which contain the proteolytic enzymes needed for the degradation of the 
autolysosome content (Klionsky and Ohsumi, 1999).  
 Autophagy is a highly regulated process that can be induced during normal cell growth and 
differentiation but also during starvation and trophic stress periods, in order to maintain homeostasis and ensure 
cell survival (Shintani and Klionsky, 2004).  
Lithium is known to induce autophagy, by inhibiting inositol monophosphatase (IMPase; Sarkar et al, 
2005). This survival mechanism has been suggested to counteract apoptosis and neutralize damaged areas in the 
brain by isolating activated caspase-3 into autophagic vacuoles (Stadelmann et al, 1999) and therefore might be 
potentially involved in the effects of lithium against apoptosis induced by Aβ peptide. 
 8 
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2| Aims 
 
 
Taking into consideration all findings of the reported protective properties of lithium against the 
neurotoxicity of Aβ peptide (Alvarez et al, 1999; Wei et al, 2000), this experimental work was designed to clarify 
the role of lithium in the prevention of apoptotic cell death induced by amyloid-β peptide and the mechanisms 
involved.  
As previously described, exogenous administration of BDNF has a neuroprotective role against toxic 
effects of Aβ peptide (Arancibia et al, 2008). In the brain of AD patients, it was extensively reported that the 
levels of both precursor and mature forms of this neurotrophin, as well as its mRNAs, are decreased (Connor, 
1997; Peng et al, 2005; Michalski and Fahnestock, 2003 Holsinger et al, 2000; Phillips et al, 1991). In addition, it 
was also reported that expression of the complete isoform of TrkB receptor is reduced in this pathology, whereas 
the expression of TrkB-Tc is increased (Ferrer et al, 1999). Since lithium has been suggested to induce an increase 
on BDNF signalling (Fukumoto T et al, 2001) and to protect cortical neurons from glutamate excitotoxicity trough 
a mechanism dependent on TrkB receptors activation (Hashimoto, 2002), the question emerged whether lithium 
is able to protect neurons against Aβ-induced apoptosis, by a BDNF signalling dependent mechanism . Moreover, 
since lithium is an autophagy inducer (Sarkar et al, 2005) it was also investigated whether this mechanism could 
be involved in neuroprotection by lithium. 
 
Therefore, to unravel these questions and achieve the proposed aims, primary cultures of rat cortical 
neurons and cultures of PC12 cells were prepared to: 
 
Task 1 – Clarify whether lithium could prevent apoptotic cell death induced by Aβ25-35 peptide; 
Task 2 – Investigate the mechanisms underlying lithium’s potential protective effects; 
2.1 - Study the involvement of BDNF signalling in LiCl protective actions, in cultured neurons; 
2.2 - Clarify the role of lithium on autophagy induction, in PC12 cells, and to study the role of this 
process on LiCl neuroprotection in neurons 
Task 3 – Investigate whether the actions of lithium could be related to ionic changes. 
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 3| Methodology 
 
3.1– Biological model 
 
3.1.1– Primary neuronal cultures 
 
Primary cultures of rat cortical neurons were prepared from 18- to 19- day-old fetuses of Sprague-
Dawley rats. Pregnant rats were anesthetized with 30% of isoflurane in propylene glycol and subsequently, 
decapitated. The fetuses were collected in Hanks’ balanced salt solution (HBSS-1) and rapidly decapitated. After 
removal of meninges and white matter, brain cortices were collected in HBSS without Ca2+ and Mg2+ (HBSS-2). 
Then, they were mechanically fragmented, transferred and incubated, for 15 minutes at 37oC, in a HBSS-2 
solution containing 0.025% trypsin, a proteolytic enzyme used to dissociate cells in a tissue. Following 
trypsinization, cells were centrifuged three times at low speed (200-250 g), washed twice in HBSS-2 with 10% 
fetal bovine serum (FBS), to neutralize trypsin’s action, and resuspended in Neurobasal medium. Before counting 
the cells, the resulting cell suspension was filtrated to obtain a homogeneous suspension without cell clusters or 
tissue fragments. Finally, cells were cultured in, precoated with poly-D-lysine, 6-well plates (1.2x106 cells/well) for 
Western blot assays. The cultures were maintained, at 37oC in a humidified atmosphere of 5% CO2, in Neurobasal 
medium supplemented with 0.5mM L-glutamine, 25µM L-glutamic acid, 2U/mL Pen/Strep and 2% B-27 
supplement, which contains a great number of trophic and protective antioxidant compounds and prevents the 
proliferation of glial cells (Brewer et al, 1993). 
Cultures were grown for 7 days before drug exposure, which was performed within 8 days in vitro (DIV).   
 
 
3.1.2– PC12 cell cultures 
  
PC12 cells are derived from a spontaneous rat pheochromocytoma and are commonly used as model 
of neuronal differentiation. PC12 cells differentiate and acquire a neuronal-like phenotype upon incubation with 
nerve growth factor (NGF; Greene and Tischler, 1976).  
These cells were purchased from Sigma and used in preliminary flow cytometry experiments, 
performed in the United States, to investigate the role of lithium in autophagy’s induction. Cells were grown at 
37°C in a 5% CO2 humidified atmosphere in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 
essential aminoacids, 2 U/mL Pen/Strep, 0.5 mM glutamine and 10% of Fetal Bovine Serum (FBS). For flow 
cytometry experiments, cells were plated in 12-well plates, at 5x10
4
 cells/well (3.14cm
2
; 800µL of supplemented 
DMEM), the day before administration of drugs.  
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3.2– Administration of drugs 
 
3.2.1– Primary neuronal cultures 
 
Cell culture medium was removed and replaced by new culture medium without L-glutamic acid at the 
4
th
 day of culture, until the end of the experiment. 
At the 8th day of culture, drugs were added to culture medium. Cells designed for the study of apoptotic 
cell death induced by amyloid-β (Estus et al, 1997), were incubated for 24 hours in the presence or absence of 
Aβ25-35 peptide in a final concentration of 25µM. As a negative control for apoptosis, cells were also incubated, 
for 24 hours, with Z-Val-Ala-DL-Asp (OMe)-Fluoromethylketone (Z-VAD-Fmk), a caspase inhibitor.  
To evaluate the role of lithium, as a protective agent against Aβ-induced apoptosis, lithium chloride 
(LiCl) was added to cells at the same time as Aβ25-35 peptide, at different concentrations (0.5, 10 and 50 mM). 
Sodium chloride (NaCl) was also used as a control of ionic changes (Figure 6A). 
 
3.2.2– PC12 cells 
 
PC12 cells, used in flow cytometry experiments, were incubated, for 24 hours, with LiCl (10 mM) or with 
rapamycin (0.2 µM), an inducer of autophagy (Figure 6B).  
To minimize the risk of mutations, cells in a narrow range of passages (between 10 and 20) were used 
for experimentation. 
 
 
3.3– Preparation of cell lysates from neurons 
 
After 24 hours of treatment, rat cortical neurons, cultured in 6-well plates were washed twice with PBS 
and harvested with cells scrapers.  Subsequently, they were resuspended in an ice-cold lysis buffer solution, 
containing 1% NP40 (Nonidet P40); 150 mM NaCl; 50 mM Tris-base; 5 mM EDTA (Ethylenediamine Tetraacetic 
Acid); 5 mM DTT (1,4-dithiothreitol) and protease inhibitors. These lysates were then centrifuged for 10 min at 
13,000 g and the supernatants were collected and stored at -20
o
C. 
The samples prepared by the above-mentioned method were then analysed by Western Blotting 
technique to measure the levels of TrkB receptors and the formation of Caspase-3, an enzyme strongly involved 
on the apoptotic process. These samples were also used to assess the activity of this main effector caspase 
through a caspase-like activity assay. 
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3.3.1– Western Blotting 
 
To analyze the levels of TrkB receptors and of caspase-3, the Sodium dodecyl sulphate-polyacrilamide 
gel electrophoresis (SDS-PAGE) technique was used. 
The protein concentration of each sample was evaluated using the BioRad DC Protein assay Kit followed 
by absorbance measurements at 620nm.  
Samples diluted in sample buffer (350mM Tris pH 6.8; 30% glycerol; 10% SDS; 600mM DTT and 0.012% 
Bromophenol blue) were denatured at 95
o
C for 5 minutes and, 15µg of total protein were loaded and separated 
on 12 or 15% SDS-PAGE, followed by transfer onto nitrocellulose membranes. After blocking the membranes, at 
room temperature with 5% non-fat- dry milk solution in TBS- Tween 1% (TBS-T) to avoid unspecific interactions 
between the antibodies and the membranes, blots were incubated overnight at 4ºC with the primary antibodies, 
prepared in 3% Bovine Serum Albumin (BSA) in TBS-T solution, that recognized and labelled specific proteins. 
Membranes were then washed with TBS-T solution and incubated with secondary antibodies conjugated with 
horseradish
 
peroxidise (HRP, EC 1.11.1.7) for 1 hour at room temperature. Secondary antibodies were prepared 
in 5% milk in TBS-T solution.  
The proteins of interest were detected using chemiluminescent reagents (ECL Plus Western Blotting 
Detection Reagents) and X-ray films.  
Finally, optical density of each protein’s band was determined with Image-J software and, with 
subsequent normalization to each respective α-Tubulin’s band density, which was used as a loading control.    
 
 
3.3.2– Caspase-like activity assay 
 
To complement the results of caspase-3 levels obtained by Western blotting technique, 
spectrophotometric assays  were also performed to evaluate the enzymatic activity of this protease.  
General caspase-3-like activity was evaluated by enzymatic cleavage of the chromophore p-nitroanilide 
(pNA) from the substrate N-acetyl-Asp-Glu-Val-Asp (DEVD) pNA.  
The proteolytic reaction was performed with 30 µg of cytosolic protein, in lysis buffer and 100 µM 
DEVD-pNA. The reaction mixtures were incubated at 37
o
C for 1 hour, and the liberation of pNA was determined 
by measuring absorbance at 405 nm using a 96-well plate reader. 
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3.4– Preparation of samples from PC12 cells1 
 
After 24 hours of PC12 cells exposure to rapamycin or LiCl, the cell culture medium was removed. Cells 
were washed with DMEM (without phenol red), to which Acridine Orange (AO) was subsequently added. AO is a 
cationic dye that enters into acidic compartments, where it fluoresces red, and is frequently used as a method to 
measure autophagy (Darzynkiewicz et al, 1992). Cells were exposed to this dye for 15 minutes, at 37°C in a 5% 
CO2 humidified atmosphere. After this period, cell culture medium was removed; cells were washed with 
Phosphate Buffer Saline (PBS) solution and subsequently trypsinized, for 5 minutes. To neutralize trypsin’s action, 
cells were then washed with PBS 1x solution containing 2% FBS. Using a micropipette, cells were homogenized 
and collect in eppendorf tubes. Cell suspensions were then centrifuged twice (1000 rpm, for 5 minutes, at 4
o
C). 
The supernatant was discarded and the pellet was resuspended in ice-cold in Incubation Buffer (0.5% BSA in PBS 
1x). Finally, samples were analyzed by flow cytometry technique (FL1: 530 ± 30 nm, FL3: 670 nm bandpass filters) 
to detect changes in the amount of acidic compartments that correlate with the autophagic process.  
 
Observation: To avoid losing autophagic cells, which could detach from the bottom of the plates during the 
procedures, all the cell culture medium, including the solutions used to wash cells, were kept and collected in 
eppendorf tubes. These tubes were centrifuged as well and the resulting pellets were mixed with the 
corresponding samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1
 PC12 cells were used to evaluate the ability of Lithium to induce autophagy. These experiments were 
performed at the Department of Chemistry of William Jewell College, Missouri, USA and they were supervised by 
Professor Lori Wetmore. 
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A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 6 – Sequential steps performed in primary neuronal cultures (A) and in PC12 cells (B).   
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3.5– Chemicals, drugs and antibodies 
 
All the chemicals used in this experimental work were purchased from GIBCO, Invitrogen, unless 
mentioned.  
 
3.5.1– Chemicals 
 
Table 1 – Some chemicals used in the experimental work and respective provider. 
 
Chemicals Provider Used in... 
L-glutamic acid Sigma Neuronal cultures 
Pen/Strep Sigma Neuronal cultures 
DMEM Sigma PC12 cells culture 
Acridine Orange (AO) Sigma Flow cytometry  
NP 40 Fluka Preparation of Cell lysates 
Protease inhibitors 
(Complete, EDTA-free Protease Inhibitor cocktail tablets) 
Roche Cell lysates 
BioRad DC Protein assay kit Bio-Rad Protein quantification 
ECL Plus Western Blotting Detection Reagents Amersham Western Blotting 
 
 
 
3.5.2– Drugs 
 
Table 2 – Drugs used in the experimental work and respective provider. 
 
Drug Provider Stock solutions 
Aβ25-35 peptide Bachem 
Dissolved in sterile water and stored at -20
o
C. 
Stock concentrations: 1mM (Aβ peptide) and 
600mM (LiCl and NaCl) 
LiCl Merck 
NaCl  Merck 
Z-VAD-Fmk  Bachem Dissolved in DMSO and stored at -20
o
C. Stock 
concentration: 20mM (Z-VAD-Fmk) and 
500mM (Rapamycin) Rapamycin Alexis Biochemicals  
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3.5.3– Antibodies 
 
The following tables present the primary and secondary antibodies, and respective dilutions, used in this 
experimental work, as well as the provider company.  
 
Table 3 – Primary antibodies and dilutions used in Western blotting technique. 
Primary antibodies Dilution Provider 
Mouse Monoclonal anti-TrkB  1:1000 BD Biosciences (610101) 
Rabbit Polyclonal anti-α-Tubulin  1:2000 Abcam (ab4074) 
Rabbit Polyclonal anti-Caspase-3 1:1000 Santa Cruz Biotechnology (sc-7148) 
 
 
Table 4 – Secondary antibodies and dilutions used in Western blotting technique. 
Secondary antibodies Dilution Provider 
Goat anti-mouse IgG - HRP 1:15000 Santa Cruz Biotechnology 
Goat anti-rabbit IgG - HRP 
1:10000 (α-tubulin) 
 1:7500 (caspase-3) 
Santa Cruz Biotechnology 
 
 
 
3.6– Statistics 
 
The data are expressed as mean ± SEM of the n number of independent experiments. 
Independent experiments were considered to be all the results obtained from different primary cultures 
of cortical neurons, prepared from embryos of different pregnant rats.  
The significance of differences between the means of two conditions was evaluated by Student’s t test. 
To perform multiple comparisons between the means of three or more conditions a one-way ANOVA test was 
performed, followed by a Dunnet post hoc test, in which all the selected data was compared to control samples 
or Aβ peptide samples. Values of p<0.05 were considered to represent statistically significant differences.  
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4| Results and discussion 
 
 
4.1. Is LiCl able to prevent apoptosis induced by Aβ25-35 peptide? 
 
Rational 
 
Previous studies demonstrated that Aβ25-35 peptide induces apoptotic cell death in neuronal cultures 
(Estus et al, 1997; Stadelmann et al, 1999; André Santos, 2009). Lithium has proven to be neuroprotective, 
against Aβ peptide toxicity (Alvarez et al, 1999; Wei et al, 2000); however its role in Aβ-induced apoptosis is yet 
not established. 
In this project, it was investigated the putative role of LiCl in the prevention of apoptosis induced by Aβ 
peptide in neuronal cultures. For this purpose, the levels and activity of caspase-3, considered the central 
apoptotic effector enzyme responsible for many of the biochemical and morphological features of apoptosis 
(Stadelmann et al, 1999), were evaluated upon exposure of neurons to Aβ peptide or LiCl, alone or 
simultaneously. 
 
 
Results 
 
4.1.1 – Effect of Aβ25-35 peptide on the levels and activity of caspase-3  
 
Neuronal cultures with 7 DIV were incubated with Aβ25-35 peptide (25 µM) for 24 hours. The levels and 
the activity of caspase-3 were evaluated in cell lysates, prepared from these cultures, as described in 
methodologies. 
As presented on Figure 7, the levels of caspase-3, detected by western blot technique, were 11.9 ± 3.0 
fold higher in samples prepared from cells incubated with Aβ peptide, when compared with control samples 
(n=8, p<0.05). In a similar way, caspase-3 activity was also increased in neurons incubated with Aβ peptide (4.1 ± 
1.1 fold, n=7, p<0.05). 
As a negative control of caspase-3 formation and activity, cells were also incubated with Z-VAD-Fmk (20 
µM), a caspase inhibitor. The administration of this drug decreased the levels of caspase-3 and completely 
blocked its activity (n=3, p<0.05, Figure 7), in neuronal cultures treated with Aβ peptide.  
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                      A) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Aβ peptide increased caspase-3 formation and its activity in neuronal cultures. Cortical neurons were isolated 
and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated either with A25-35 
peptide (25 M) and/or Z-VAD-Fmk (20 µM), for 24h. In A, a representative Western blot of caspase-3 levels is provided. 
Histogram B shows mean ± SEM values of the ratio of caspase 3/ α-tubulin (One-way ANOVA test, *p<0.05, n=3-8).  
Histogram C shows mean ± SEM values of caspase-3 activity (One-way ANOVA test,*p<0.05, n=3-8). Dotted line represents 
the control values (CTR, no added drugs). 
 
 
4.1.2 – Effect of LiCl on the levels and activity of caspase-3  
 
To evaluate the influence of lithium on the expression and activity of caspase-3, these two parameters 
were evaluated on samples prepared from neurons incubated, for 24 hours, with different concentrations of LiCl 
alone.  
The results show that LiCl (0.5 mM and 50 mM) was not able to significantly modify caspase-3 
expression (n=8, Figure 8A) or its activity (n=3-6, Figure 8B). On the other hand, samples treated with LiCl (10 
mM) showed an increase of 1.7 ± 0.3 fold in caspase-3 levels and a significant increase of 1.9 ± 0.2 fold in 
caspase-3 activity, when compared with control samples (n=7-8, p<0.05, Figure 8).  
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Figure 8 – Levels and activity of caspase-3 in neuronal cultures incubated with LiCl. Cortical neurons were isolated and 
cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated with increasing 
concentrations of LiCl (0.5; 10 and 50 mM), for 24h. Histogram A shows mean ± SEM values of the ratio of caspase 3/ α-
tubulin (One-way ANOVA test, *p<0.05, n=7). Histogram B shows mean ± SEM values of caspase-3 activity (One-way ANOVA 
test, *p<0.05, n=8). Dotted line represents the control values (CTR, no added drugs).  
 
 
4.1.3 – Effect of LiCl on the levels and activity of caspase-3 upon simultaneous 
incubation with Aβ25-35 peptide   
 
To examine wheter lithium reduced apoptosis induced by Aβ peptide, levels and activity of caspase-3 
were evaluated in rat cortical neurons incubated, simultaneously,  with Aβ peptide and with two different 
concentrations of LiCl (0.5 and 10 mM), for 24 hours. 
In the presence of Aβ25-35 peptide (25 µM), the administration of a lower concentration of LiCl (0.5mM) 
did not significantly affect  the high levels (n=4-8, Figure 9B) and activity of caspase-3 (n=3-7, Figure 9C), induced 
by Aβ peptide. On the other hand, the administration of LiCl (10 mM) significantly reduced these two 
parameters, by decreasing the levels of caspase-3 by aproximatly 71.3 ± 11.1%  (n=5-8, p<0.05, Figure 10B) and 
its activity, by 48.8 ± 8.4% (n=7-8, p<0.05, Figure 10C), when compared with cells treated with Aβ peptide alone.  
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     A) 
 
 
 
 
 
 
 
 
 
 
Figure 9 – LiCl (0.5 mM) did not reduce, significantly, the increase of caspase-3 levels and activity, induced by Aβ peptide. 
Cortical neurons were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells 
were incubated either with LiCl (0.5 mM) and/or A25-35 peptide (25 M), for 24h. In A, a representative Western blot of 
caspase-3 levels is provided. Histogram B shows mean ± SEM values of the ratio of caspase 3/ α-tubulin (One-way ANOVA 
test, *p<0.05, n=8). Histogram C shows mean ± SEM values of caspase-3 activity (One-way ANOVA test, *p<0.05, n=6-7). 
Dotted line represents the control values (CTR, no added drugs).  
 
 
  A) 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – LiCl (10 mM) reduced the increase of caspase-3 levels and activity, induced by Aβ peptide. Cortical neurons 
were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated with 
LiCl (10 mM) and/or A25-35 peptide (25 M), for 24h. In A, a representative Western blot of caspase-3 levels is provided. 
Histogram B shows mean ± SEM values of the ratio of caspase 3/ α-tubulin (One-way ANOVA test, *p<0.05, n=5-8). Histogram 
C shows mean ± SEM values of caspase-3 activity (One-way ANOVA test, *p<0.05, n=7).  Dotted line represents the control 
values (CTR, no added drugs). 
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Discussion 
 
The results showed that LiCl (10 mM), but not LiCl (0.5 mM), significantly reduced apoptosis induced by 
Aβ25-35 peptide. 
The induction of apoptotic cell death by Aβ peptide was already extensively observed (Stadelmann et al, 
1999), including by researchers in our laboratory (André Santos, 2009). In this project, it was shown that 
exogenous administration of Aβ25-35 peptide (25 µM) to neuronal cultures induces a significant increase in 
caspase-3 levels and its activity. Caspase-3 is considered the central apoptotic effector enzyme, responsible for 
many of the biochemical and morphological features of apoptosis. Activation of this protease represents an 
irreversible step in the cell death pathway, and cells containing activated caspase-3 are prone to die (Stadelmann 
et al, 1999).  
The mechanisms through which Aβ peptide triggers apoptosis are not completely clarified yet. In 
cultured neurons, administration of Aβ peptide has been correlated with an increase in phosphorylation of Tau 
protein (Alvarez et al, 1999; Busciglio et al, 1995; Ferreira et al, 1998; Takashima et al, 1998). This is a very 
interesting finding since Tau protein, when hyperphosphorylated, forms the fibrillary tangles observed in AD. In 
fact, it has been hypothesized that tau hyperphosphorylation might lead to microtubule destabilization and tau 
protein aggregation, thus causing a deficit of axonal transport which could eventually result in neuronal cell 
death (Goedert et al, 1998; Lovestone et al, 1997; Alonso et al, 1996). 
Beyond that, it was already shown that Aβ peptide activates JNK pathway in cortical neurons 
(Morishima et al, 2001). Activated JNK is required for phosphorylation and activation of c-Jun transcription 
factor, which in turn stimulates the transcription of several key target genes, including the death inducer Fas 
ligand (FasL, Morishima et al, 2001). This protein induces apoptosis through binding to its death receptor Fas, 
followed by activation of the caspase cascade (Nagata et al, 1997). Activation of the JNK pathway as a possible 
mechanism for Aβ peptide toxicity is supported by the fact that Aβ peptide-induced apoptosis is dependent on 
protein synthesis (Pike et al, 1996), which might reflect a requirement for JNK-dependent transcription.   
Other processes, such as mitochondrial dysfunction (Casley et al, 2002), perturbation of intracellular 
calcium homeostasis (reviewed in LaFerla, 2002), and downregulation of BDNF functions (Tong et al, 2004), have 
also been suggested to be involved in Aβ peptide toxicity.  
 
Previously, it was shown that, in differentiated hippocampal neurons, lithium (20 mM) is able to 
facilitate apoptotic signalling induced by stimulation of Fas (Song et al, 2004). Moreover, it was also reported 
that lithium promotes TNFα-induced cytotoxicity (Beyaert et al, 1989, 1992 and 1993; Schotte et al, 2001). 
Therefore, the results obtained upon incubation of neuronal cultures with LiCl (10 mM) alone, where a significant 
increase of caspase levels and activity was observed (Figure 8), might be a consequence of Fas and TNFα 
receptors activation, which are involved in the extrinsic apoptotic signalling pathway.  
From a clinical perspective, lithium is not an ideal drug, being both teratogenic and toxic at doses close 
to those required for therapeutic benefit (Klein et al, 1996).  
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Although a 10 mM concentration might induce apoptosis, as the results here presented indicate, this 
concentration is extensively used in in vitro experiments to maximize lithium effects. For that reason, it was 
decided to continue using this concentration in the experimental work. 
Curiously, incubation of cells with a higher concentration of LiCl (50 mM) did not increase the levels and 
activity of caspase-3. On the contrary, the results obtained show that these two parameters of apoptosis did not 
change upon cellular incubation with LiCl (50 mM), compared to control conditions. These interesting results 
might reflect the toxicity of lithium ion. Probably, at this high concentration, lithium induces necrosis, a cell death 
process that does not require caspase activation. In the future, it would be useful to perform cytotoxicity assays, 
such as the uptake of Propidium Iodide or the LDH release assay, to confirm this hypothesis.   
 
The data obtained upon simultaneous incubation of neurons with LiCl and Aβ peptide, show that LiCl at 
10 mM, but not at 0.5 mM, reduced the high activity and levels of caspase-3, induced by the neurotoxic peptide, 
suggesting that, at that concentration, LiCl is able to protect neuronal cultures from Aβ peptide-induced 
apoptosis. In fact, neuroprotective effects of LiCl, assigned to lithium ion, were previously described by Alvarez 
and collaborators (1999). These investigators showed that, in the presence of LiCl (10 mM), the cell viability of rat 
cortical neurons treated with Aβ1-40 peptide (25 µM) increased.  Moreover, it was shown that this is not merely a 
consequence of a possible delay in neuronal cell death, since the effect is still observed 4 days after Aβ 
administration (Alvarez et al, 1999). In our experimental work a different fragment, Aβ25-35 peptide, was used, 
but it has been previously shown that this fragment has similar effects to Aβ1-40 peptide (Yanker et al, 1990; 
Imaizumi, 1999). Nevertheless, both the results obtained by our laboratory and Alvarez and collaborators 
demonstrate neuroprotective actions of LiCl (10mM) against Aβ peptide toxicity. However, it is important to 
emphasize that in the present work, a specific type of cellular death, apoptosis, was evaluated, in contrast to the 
previous work (Alvarez et al, 1999), which only analyzed cell viability (MTT assay). 
 
Since the mechanisms underlying apoptosis induced by Aβ peptide are not completely clarified yet, it is 
not easy to predict how LiCl exerts its neuroprotective effects. Currently, several actions of lithium on different 
processes suggested to be involved in Aβ peptide-induced cell death have been described. As mentioned before, 
Aβ peptide increases Tau phosphorylation (Alvarez et al, 1999; Busciglio et al, 1995; Ferreira et al, 1998; 
Takashima et al, 1998), which has been suggested to cause neuronal cell death (Goedert et al, 1998; Lovestone 
et al, 1997; Alonso et al, 1996). According to this view, protein kinases responsible for tau protein 
phosphorylation have a crucial role on cell death induced by Aβ peptide. Lithium is a known inhibitor of glycogen 
synthase kinase-3 (GSK-3; reviewed in Jope, 2003), which phosphorylates Tau protein. Therefore, 
neuroprotective effects of LiCl, observed in this project, may be a consequence of a decrease in phosphorylation 
of tau protein due to GSK-3 inhibition (Figure 11).  
However, data obtained in an in vivo study showed that lithium inhibits Aβ peptide-induced caspase 
activation but not tau phosphorylation (Ghribi et al, 2003). An explanation for these results is that tau 
phosphorylation might be mediated by other protein kinases activated by Aβ peptide, other than GSK-3. 
Nevertheless, these data also highlight the fact that it is still not clear if tau hyperphosphorylation is required for 
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cell death induced by Aβ peptide and therefore, further experiments will have to be performed to confirm this 
hypothesis. 
 
 
 
 
 
 
 
 
Figure 11 – Neuroprotection of lithium against Aβ peptide toxicity:  decrease of Tau protein phosphorylation. 
Administration of Aβ peptide has been correlated with the increase of Tau phosphorylation (Alvarez et al, 1999; Busciglio et 
al, 1995; Ferreira et al, 1998; Takashima et al, 1998), a protein involved in microtubule stabilization. When 
hyperphosphorylated, this protein aggregates and forms the fibrillary tangles observed in AD’s brains. Lithium is an inhibitor 
of GSK-3 which phosphorylates Tau protein. Although, presently, it is still unknown if an increase of Tau phosphorylation 
leads to apoptosis, inhibition of GSK-3 by lithium and subsequent decrease of Tau phosphorylated is a putative mechanism 
for lithium’s neuroprotection against Aβ toxicity.   
 
The ability of lithium to prevent apoptosis and its failure to prevent tau phosphorylation, following Aβ 
peptide administration, correlates with the inhibition of JNK and its substrate c-Jun (Ghribi et al, 2003). Since 
JNK/c-Jun pathway is crucial for the transcription of the gene that encodes for FasL protein, which in turn is 
involved in an apoptotic mechanism, inhibition of this pathway by lithium may also be an explanation for its 
protective role (Figure 12).  
This hypothesis is supported by evidences that show that lithium inhibits JNK/c-Jun pathway, in trophic 
deprivation circumstances (Hongisto et al, 2003).  
 
 
 
 
 
 
 
 
 
 
Figure 12 – Neuroprotection of lithium against Aβ peptide toxicity: inhibition of JNK/c-Jun pathway. Aβ peptide induces 
activation of this signalling pathway, which may culminate in apoptosis due to an increase of FasL and subsequent binding to 
its death receptor (Morishima et al, 2001; Nagata et al, 1997).  There is evidence that, in vivo, lithium inhibits JNK/c-Jun 
pathway (Ghribi et al, 2003). Therefore, inhibition of this signalling pathway is a hypothetical mechanism for for lithium’s 
neuroprotection against Aβ toxicity.   
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Another possibility for the neuroprotective effects of LiCl against apoptosis induced by Aβ peptide is a 
putative increase of neurotrophins levels or its receptors.  
In rat brain, it was shown that chronic lithium treatment increases the expression of BDNF (Fukumoto et 
al, 2001), which has well known neuroprotective effects (André Santos, 2009; Arancibia, 2008).   In addition, it 
was reported that treatment of cortical neurons with lithium (1mM), for 6 days, increases intracellular BDNF 
within 3 days, and the levels of phosphorylated TrkB within 5 days (Hashimoto et al, 2002). Figure 13 presents a 
schematic representation of this hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Neuroprotection of lithium against Aβ peptide toxicity: increase of BDNF levels and TrkB receptors activation.  
At a sublethal concentration (200 µM), Aβ peptide interferes with BDNF-induced activation of PI3K and MAPK pathways (Tong 
et al, 2004), which are crucial for neuronal survival.  Chronic treatment with lithium, in rat brain, is suggested to increase 
BDNF levels (Fukumoto et al, 2001). Therefore, this action is a hypothetical mechanism for lithium’s neuroprotection against 
Aβ toxicity, since it would counteract the negative action of Aβ peptide and decrease apoptosis.   
  
  
 Lithium has the ability to induce autophagy (Sarkar et al, 2005), a survival mechanism that has been 
suggested to counteract apoptotic cascade in neurons, by isolating activated caspase-3 into autophagic vacuoles 
(Stadelmann et al, 1999). Therefore, LiCl neuroprotection against Aβ peptide toxicity could be mediated by its 
capacity to induce autophagy (Figure 14).    
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Figure 14 – Neuroprotection of lithium against Aβ peptide toxicity: induction of autophagy. Apoptosis induced by Aβ 
peptide might be prevented by LiCl through autophagy induction. First, an “isolation” membrane would form around the 
cytoplasmic regions containing the activated caspase-3, induced by Aβ peptide. The resulting autophagosomes 
would then fuse with lysosomes forming autolysosomes that would contained the proteolytic enzymes needed 
for the degradation of caspase-3 (adapted from Stadelmann et al, 1999; Klionsky and Ohsumi, 1999).  
  
 
Administration of LiCl to the cell culture medium will lead to the dissociation of this salt in its 
components, Li
+
 and Cl
- 
ions, and consequently change the ionic constitution of the medium. Somehow these 
changes may modify the way Aβ peptide exerts its toxicity or even the way cells respond to it.  
 
Of all the hypotheses mentioned before, in this master experimental work three hypotheses were 
tested: 1) whether neuroprotective effects of LiCl against Aβ-induced apoptosis were mediated by an 
improvement of BDNF/TrkB signalling; 2) whether autophagy had a role in the actions of LiCl and 3) whether the 
neuroprotection mediated by LiCl was a consequence of ionic changes.      
 
 
4.2. Which are the mechanisms underlying LiCl protective effects 
against apoptosis induced by Aβ25-35 peptide? 
 
4.2a – Involvement of BDNF/TrkB signalling 
 
Rational 
 
Through a process of alternative splicing, the gene for TrkB receptor may encode for two distinct 
proteins: the truncated isoform of the TrkB receptor, TrkB-Truncated (TrkB-Tc) and the complete isoform, TrkB-
Full length (TrkB-FL). The truncated isoform is similar to the complete isoform in its extracellular domain; 
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however, it lacks the intracellular kinase signaling domain, responsible for many of the actions of neurotrophins. 
As a consequence of these structural differences, the molecular weights of these two isoforms are different, 
which allows their distinction by Western blotting technique. TrkB-FL isoform has a molecular weight of 145kDa, 
whereas the truncated form has 95kDa (Eide et al, 1996). 
BDNF binding to TrkB-FL and to TrkB-Tc receptors has very distinct responses. Evidence indicates that, 
positive actions of BDNF in neuronal survival, differentiation and plasticity are result of its binding to the 
complete isoform of TrkB receptor, TrkB-FL. On the other hand, the truncated isoform TrkB-Tc acts as an 
inhibitor of BDNF signalling for the following reasons: 1) TrkB-Tc does not have tyrosine kinase activity and, 
therefore, it is not able to activate all the survival signalling pathways related with BDNF (Figure 5; Middlemas et 
al, 1991); 2) since TrkB-Tc has affinity for BDNF, it may compete with TrkB-FL (Beck et al, 1993) and finally 3) 
TrkB-Tc is a negative modulator of TrkB-FL because it can associate with the complete isoform, inhibiting the 
homodimerization of TrkB-FL required for the signalling transduction (Eide et al, 1996).  
 
As previously mentioned, both levels of BDNF and TrkB receptors are changed in the brain of AD 
patients. Previous studies showed that the levels of this neurotrophin (Connor, 1997), along with the levels of its 
precursor (Peng et al, 2005; Michalski and Fahnestock, 2003) are decreased in the brain of AD patients. In 
addition, it was shown that expression of the TrkB-FL isoform is decreased and TrkB-Tc increased, in the frontal 
cortex and hippocampus of individuals affected by AD (Ferrer et al, 1999). Recently, these changes were 
correlated with the presence of Aβ peptide. Experiments previously performed in the host laboratory showed 
that exposure of neuronal cultures to Aβ25-35 peptide (25 µM) induces an increase in the levels of TrkB-Tc and a 
decrease of TrkB-FL levels (André Santos, 2009).  
Following these results and since it has been shown that lithium activates PI3K/Akt and MAPK pathways 
that are involved in cell survival mechanisms (Figure 5), which effects have been correlated with an increase of 
BDNF expression and TrkB phosphorylation (reviewed in Chuang, 2004), in this project the possibility that LiCl 
exert its protection, against apoptosis induced by Aβ peptide, through improving BDNF/TrkB pathway was 
explored. For that purpose, whether LiCl was able to reverse the changes in the levels of TrkB-FL and TrkB-Tc 
isoforms, induced by Aβ peptide, was investigated.   
 
 
Results 
 
4.2a.1 –Effect of Aβ peptide on TrkB receptor levels  
 
 Neuronal cultures with 7 DIV were incubated, for 24 hours, with Aβ25-35 peptide (25 µM) and the 
densities of the two isoforms of TrkB receptor were assessed by Western blot technique. 
As verified in previous experiments performed in the host laboratory  (André Santos, 2009), results 
obtained in this experimental work show that exogenous administration of Aβ peptide induces changes in both 
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isoforms and significantly increases the levels of TrkB-Tc (2.8 ± 0.4 fold, n=10, p<0.05, Figure 15B), when 
compared with control samples. 
Since BDNF actions mediated by TrkB-FL activation may be counteracted by activation of TrkB-Tc 
receptors, changes in the proportion between the levels of these two isoforms are more important than 
individual changes, because they might indicate changes in BDNF signalling. Thus, the TrkB-FL/TrkB-Tc ratio was 
calculated afterwards. As shown in Figure 15D, this ratio significantly decreased upon exogenous administration 
of Aβ peptide to neurons in culture, compared to control samples (70.2 ± 4.7%, n=10, p<0.05).  
 
 
                                              A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – Incubation of neuronal cultures with Aβ25-35 peptide induced changes in TrkB receptor levels and in the 
proportion between the two isoforms. Cortical neurons were isolated and cultured for 7 days before incubation with drugs, 
as described in Methodologies. Cells were incubated with A25-35 peptide (25M), for 24h. In A, a representative Western blot 
of the levels of TrkB-FL and TrkB-Tc receptors is provided. Histogram B shows mean ± SEM values of the ratio of TrkB-FL/ α-
tubulin (One-way ANOVA test, *p<0.05, n=10). Histogram C shows mean ± SEM values of TrkB-Tc/ α-tubulin (One-way ANOVA 
test, *p<0.05, n=10). Histogram D shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, 
*p<0.05, n=10). Dotted line represents the control values (CTR, no added drugs).  
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4.2a.2 – Effect of LiCl on TrkB receptor levels  
 
The results obtained show that LiCl (10 mM) induced a significant increase (2.8 ± 0.4 fold) in the levels of 
TrkB-FL isoform (n=12, p<0.05, Figure 16A), in comparison to control samples. On the other hand, both 10 and 
50mM concentrations of LiCl increased, significantly, the levels of TrkB-Tc isoform (1.8 ± 0.3 and 3.9 ± 0.3 fold, 
respectively, n=10-12, p<0.05, Figure 16B). 
The calculation of TrkB-FL/TrkB-Tc ratio revealed that only LiCl (50 mM) induced significant changes in 
the proportion between the two isoforms of the TrkB receptor which is  58.2 ± 6.1 % lower than in control 
situations (n=10, p<0.05; Figure 16D). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 – TrkB receptor levels in neuronal cultures incubated with LiCl. Cortical neurons were isolated and cultured for 7 
days before incubation with drugs, as described in Methodologies. Cells were incubated with crescent concentrations of LiCl 
(0.5; 10 and 50 mM), for 24h.  Histogram A shows mean ± SEM values of the ratio of TrkB-FL/ α-tubulin (One-way ANOVA 
test, *p<0.05, n=12).  Histogram B shows mean ± SEM values of TrkB-Tc/ α-tubulin (One-way ANOVA test, *p<0.05, n=10-12). 
Histogram C shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, *p<0.05, n=10). Dotted 
line represents the control values (CTR, no added drugs).  
 
 
4.2a.3 – Effect of LiCl on TrkB receptor levels upon simultaneous incubation with 
Aβ peptide  
 
Incubation of cultured neurons with LiCl (0.5mM), in the presence of Aβ peptide, did not change the 
effects of this neurotoxic peptide on the levels of TrkB-FL and TrkB-Tc receptors, and consequently, on the 
proportion between these two isoforms (n=5, Figure 17B, 17C and 17d). 
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                                       A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 – LiCl (0.5 mM) did not change TrkB-FL and TrkB-Tc levels neither the proportion between the two isoforms, in 
cortical neurons treated with Aβ peptide. Cortical neurons were isolated and cultured for 7 days before incubation with 
drugs, as described in Methodologies. Cells were incubated with LiCl (0.5 mM) and/or A25-35 peptide (25 M). In A, a 
representative Western blot of the levels of TrkB-FL and TrkB-Tc receptors is provided. Histogram B shows mean ± SEM values 
of the ratio of TrkB-FL/ α-tubulin (One-way ANOVA test, *p<0.05, n=10-12). Histogram C shows mean ± SEM values of the 
ratio of TrkB-Tc/ α-tubulin (One-way ANOVA test, *p<0.05, n=10-12). Histogram D shows mean ± SEM values of the ratio of 
TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, *p<0.05, n=10-12). Dotted line represents the control values (CTR, no added 
drugs).  
 
Conversely, incubation of cultured neurons with a higher concentration of LiCl (10 mM), in the presence 
of Aβ peptide, significantly revert the Aβ-induced changes on TrkB-FL receptor levels. In these conditions, TrkB-FL 
levels increased 2.0 ± 0.3 fold, when compared to samples incubated with Aβ peptide alone (n=7-12, p<0.05, 
Figure 18B), while TrkB-Tc levels remained unchanged (n=10-12, Figure 18C).  Consequently, the proportion 
between the two isoforms of TrkB receptor was restored (Figure 18D). 
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                                     A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – LiCl (10 mM) increased TrkB-FL levels and the proportion TrkB-FL:TrkB-Tc, in cortical neurons treated with Aβ 
peptide. Cortical neurons were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. 
Cells were incubated with LiCl (10 mM) and/or A25-35 peptide (25 M). In A, a representative Western blot of the levels of 
TrkB-FL and TrkB-Tc receptors is provided. Histogram B shows mean ± SEM values of the ratio of TrkB-FL/ α-tubulin (One-way 
ANOVA test, *p<0.05, n=7-12). Histogram C shows mean ± SEM values of the ratio of TrkB-Tc/ α-tubulin (One-way ANOVA 
test, *p<0.05, n=10-12). Histogram D shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, 
*p<0.05, n=7-12). Dotted line represents the control values (CTR, no added drugs). 
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4.2b – Induction of autophagy: 
 
Rational 
 
Lithium (10 mM) has been described as an inducer of autophagy (Sarkar et al, 2005). This is a highly 
regulated process that can be induced during normal cell growth and differentiation but also during periods of 
starvation, in order to maintain homeostasis and ensure cell survival (Shintani and Klionsky, 2004). This process 
has been suggested to counteract apoptosis and neutralize damaged areas in the brain by isolating activated 
caspase-3 into autophagic vacuoles (Stadelmann et al, 1999). For that reason, in this project the possibility of 
autophagy being involved in the neuroprotective effects of LiCl, against apoptosis induced by Aβ peptide, was 
also explored. 
 
 
Results 
 
Initially, it was analyzed whether the neuroprotective effect of LiCl against Aβ-induced apoptosis was 
dependent on autophagy by blocking this process with 3-methyladenine (3-MA), an autophagic inhibitor. For that 
purpose, 3-MA (10 mM) was added to the cell culture medium 30 minutes before Aβ25-35 peptide and/or LiCl and 
caspase-3 levels were assessed in cell lysates, by western blotting technique. 
Incubation of neurons with 3-MA in the presence of Aβ peptide and LiCl (10mM) significantly 
decreased the levels of caspase-3, when compared to samples exposed to Aβ peptide alone (67.6 ± 12.8%, n=4-8, 
p<0.05, Figure 19).  
 
 
 
 
 
 
 
 
Figure 19 – Influence of 3-MA in the levels of caspase-3. Cortical neurons were isolated and cultured for 7 days before 
incubation with drugs, as described in Methodologies. Cells were incubated, for 24h, with A25-35 peptide (25M) and or LiCl 
(10mM) and/or 3-MA (10mM). Histogram shows mean ± SEM values of the ratio of caspase 3/ Tubulin (One-way ANOVA test, 
*p<0.05, n=4-8).  Dotted line represents the control values (CTR, no added drugs). 
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Since the inhibitor of autophagy, 3-MA, did not block the neuroprotective effect of LiCl, this could mean 
that, even being an inducer of autophagy, LiCl effect upon Aβ toxicity was not mediated by this process. 
Therefore, it was preformed experiments to confirm if LiCl (10 mM) was, in fact, inducing autophagy. Due to 
technical problems, it was not possible to confirm this information on neurons. To overcome the problem and 
confirm the induction of autophagy by LiCl, preliminary flow cytometry experiments using PC12 cells were 
performed. This cell line is derived from a spontaneous rat pheochromocytoma and is commonly used as model 
of neuronal differentiation by exposer to NGF (Greene and Tischler, 1976).  
Changes in autophagic flux were evaluated by exposing cells to Acridine Orange (AO), a cationic dye that 
enters into acidic compartments and emits orange light (590 – 620 nm) when excited in the range of 450 – 495 
nm, i.e., with blue light. This property allows AO to enter into lysosomes and autolysosomes, which are involved 
in the autophagic process. For that reason this dye is frequently used as method to monitor autophagy 
(Darzynkiewicz et al, 1992). 
 
PC12 cells were incubated, for 24 hours, with LiCl (10 mM) and with Rapamycin (0.2 µM), as a positive 
control for autophagy. This drug induces autophagy by inhibiting a negative regulator of this process, the 
mammalian target of rapamycin (mTOR; Kamada et al, 2000). After this incubation period, cells were exposed to 
AO and cell samples were analyzed by flow cytometry (FL1: 530 ± 30 nm, FL3: 670 nm bandpass filters) to 
evaluate changes in the amount of acidic compartments, namely, autolysosomes. 
Preliminary results suggest that LiCl (10 mM) induces an increase in the amount of acidic compartments 
in PC12 cells (2.4 ± 0.7 fold, n=3, Figure 20B), as well as rapamycin (Figure 20D). 
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        A) 
 
 
 
 
 
 
 
 
B)                 C) 
 
 
 
  
 
 
 
    D) 
 
 
 
 
 
 
Figure 20 – Induction of autophagy in PC12 cells. In A, an explanatory scheme of the graphical data obtained in flow 
cytometry experiments is presented. Histogram B shows mean ± SEM values of the percentage of autophagic cells incubated 
with LiCl (10mM), for 24h. Dotted line represents the control values (CTR, no added drugs). In C is presented a representative 
experiment showing results obtained in Pc12 cells incubated with or without LiCl (10mM). Histogram D shows mean ± SEM 
values of the percentage of autophagic cells incubated with rapamycin (0.2µM), for 24h (n=2). Dotted line represents the 
control values (CTR, no added drugs). 
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Discussion 
 
From the experiments performed to investigate potential mechanisms for LiCl neuroprotective effects, 
against Aβ peptide-induced apoptosis, it was observed that LiCl (10 mM) reverted, in neuronal cultures, the 
changes induced by Aβ peptide in TrkB receptor levels. In addition, results obtained in preliminary flow 
cytometry experiments, using PC12 cells, showed that, at this concentration LiCl was also able to induce 
autophagy. However, further experiments performed on neuronal cultures using 3-MA suggest that autophagy 
may not be mediating LiCl effects on Aβ peptide toxicity. 
  
Previously, it was reported that chronic lithium treatment increases the expression of BDNF in rat brain 
(Fukumoto et al, 2001). Moreover, it was reported that treatment of cortical neurons with lithium increases 
intracellular BDNF, as well as TrkB receptor phosphorylation (Hashimoto et al, 2002). This elevation of BDNF by 
lithium has been suggested to be essential for this drug to protect cortical neurons from glutamate excitotoxicity, 
and BDNF/TrkB pathway to mediate many of the down-stream effectors induced by lithium (Hashimoto et al, 
2002; Chuang, 2004), as activation of PI3K/Akt (Chalecka-Franazsek and Chuang, 1997) and MEK/Erk pathways 
(Kopnisky et al, 2002), which contribute to cell survival.  
The levels of both BDNF and TrkB receptors are changed in AD patients (Connor, 1997; Michalski and 
Fahnestock, 2003; Ferrer et al, 1999). Recent information suggests a causal relation between the presence of Aβ 
peptide and the decrease in the levels of BDNF and TrkB-FL receptor (André Santos, 2009; Arancibia et al, 2010).   
Considering the information previously described, that suggests a strong relation between lithium and 
BDNF/TrkB pathway and also a correlation between changes in the levels of TrkB receptors with the presence of 
Aβ peptide, in the present project it was investigated if LiCl could reverse the changes in the levels of TrkB 
receptors caused by Aβ peptide and therefore the possibility of LiCl neuroprotective effects be mediated by an 
improve of BDNF/TrkB transducing system.   
The results obtained show that, under the experimental conditions, administration of Aβ  peptide 
significantly increased the levels of TrkB-Tc receptors and, consequently, decreased the TrkB-FL/TrkB-Tc ratio. 
This data is in accordance with previous data obtained in the host laboratory (André Santos, 2009), which 
showed, for the first time, a direct correlation between Aβ peptide and changes in the levels of TrkB receptors.  
This causal relation between the levels of TrkB receptors and Aβ peptide is supported by clinical investigation 
that show that BDNF levels and TrkB-FL density are decreased and TrkB-Tc increased, in brain tissue samples 
taken from AD’s patients (Connor et al, 1997; Ferrer et al, 1999). 
Taking into consideration the above-mentioned evidences and the opposite actions of TrkB-FL and TrkB-
Tc isoforms we can correlate the increase of TrkB-Tc levels, and consequent decrease in TrkB-FL/ TrkB-Tc ratio, to 
a possible decline in the beneficial actions of endogenous BDNF.    
Results obtained upon incubation of neuronal cultures with different concentrations of LiCl alone, 
revealed that only the highest concentration (50 mM) was able to significantly change the proportion between 
the two isoforms of TrkB receptor. Since LiCl (50 mM) is supposed to be lethal to cells, the increase of TrkB-Tc 
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levels, and the consequential decrease of the TrkB-FL/ TrkB-Tc ratio, may be a negative outcome of lithium 
toxicity.  
Simultaneous incubation of neuronal cultures with Aβ peptide and LiCl showed that LiCl (10 mM) was 
able to reverse the Aβ peptide-induced changes in TrkB receptors. At this concentration, LiCl significantly 
increased the levels of TrkB-FL receptors and slightly decreased TrkB-Tc, relatively to cells treated with Aβ 
peptide alone, which restored the TrkB-FL/TrkB-Tc ratio. The reversion of the Aβ peptide-induced changes in 
TrkB receptor levels by LiCl (10 mM), are concomitant with the reduction of the high levels and activity of 
caspase-3, also induced by Aβ peptide. Therefore these results support the hypothesis that the neuroprotective 
effects of LiCl, against apoptosis induced by Aβ peptide, might involve BDNF/TrkB pathway. This hypothesis is 
further supported by the fact that experiments performed last year in the host laboratory revealed a similar 
“recovery pattern” upon exogenous administration of BDNF (20 ng/mL) to cortical neurons treated with Aβ 
peptide.  Moreover, this last information accentuates the possibility of LiCl protective effects, against Aβ peptide 
toxicity, being a consequence of an increase in endogenous BDNF, which was already reported in situations of 
glutamate excitotoxicity (Hashimoto et al, 2002; Chuang, 2004). To confirm this hypothesis, in future we plan  to 
measure BDNF levels, by Enzyme Linked Immuno Sorbent Assay (ELISA), and also to use a scavenger of BDNF to 
evaluate if this neurotrophin is in fact mediating neuroprotective effects of LiCl. 
In 2004, Tong and collaborators reported that, at sublethal concentrations (200 µM), Aβ1-42 peptide 
interferes selectively with some BDNF-induced signal transduction pathways in cortical neurons, but does not 
interfere with BDNF binding to its TrkB receptors and following phosphorylation and activation (Tong et al, 2004). 
This study highlights the fact that TrkB-FL and TrkB-Tc levels do not reflect the activation state of TrkB receptors. 
Therefore, it is fundamental to perform, in the future, further experiments to  understand if the proportion 
between these two isoforms of TrkB receptor is correlated with the activation of survival signaling pathways, 
which would definitely explain the decrease of caspase-3 levels and activity induced by LiCl (10 mM), in neurons 
treated with Aβ peptide.  
 
Since lithium (10mM) has been described as an inducer of autophagy (Sarkar et al, 2005), a process 
frequently associated with cell survival, in this experimental work, the potential involvement of autophagy in LiCl 
protective effects against Aβ peptide-induced apoptosis was also studied.  
It was not possible to confirm the induction of autophagy by LiCl (10 mM) in neurons. However, 
preliminary experiments performed in PC12 cells revealed that, at neuroprotective concentrations, LiCl was able 
to induce autophagy. Thus, assuming that LiCl (10 mM) is also able to induce autophagy in neurons and that this 
process counteracts apoptotic cell death (Stadelmann et al, 1999), inhibition of LiCl-induced autophagy by 3-MA 
would lead to an increase of apoptotic markers. Since the results obtained in this project upon incubation of 
neuronal cultures with 3-MA, in the presence of LiCl (10 mM) and Aβ peptide, did not show an increase of 
caspase-3 levels (Figure 19), compared to samples incubated with Aβ peptide alone, this might indicate that 
autophagy does not mediate the neuroprotective effects of LiCl against apoptosis induced by Aβ peptide.   
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Nevertheless, further experiments will have to be done to confirm our statement, even because a recent 
study reported that 3-MA under nutrient-rich conditions and prolonged periods of treatment (up to 9h), as the 
ones used in our project, promotes autophagy instead of inhibit this process (Wu et al, 2010). 
 
 
4.3. Are the protective effects of LiCl a result of changes in ionic 
concentrations? 
 
Rational 
 
To evaluate whether LiCl effects on caspase-3 levels and activity, as well as on TrkB receptor levels, in 
the presence of Aβ peptide, were a consequence of changes in ionic concentrations, all the experiments 
performed with LiCl were reproduced using NaCl. 
 
 
Results 
 
4.3.1 – Effect of NaCl on the levels and activity of caspase-3  
 
Incubation of neuronal cultures with increasing concentrations of NaCl (0.5; 10 and 50 mM), for 24 
hours, did not significantly change caspase-3 levels (n=3-5, p>0.05, Figure 21A) nor its activity (n=3, p>0.05, 
Figure 210B).   
 
 
 
 
 
 
 
 
Figure 21 – Levels and activity of caspase-3 in neuronal cultures incubated with NaCl. Cortical neurons were isolated and 
cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated with crescent 
concentrations of NaCl (0.5; 10 and 50 mM), for 24h. Histogram A shows mean ± SEM values of the ratio of caspase 3/ 
Tubulin (n=3-5).  Histogram B shows mean ± SEM values of caspase-3 activity (n=3). Dotted line represents the control values 
(CTR, no added drugs). 
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4.3.2 – Effect of NaCl on the levels and activity of caspase-3 upon simultaneous 
incubation with Aβ25-35 peptide 
   
Administration of NaCl (0.5 mM) significantly reduced the high levels of caspase-3, induced by Aβ 
peptide (77.4 ± 9.0% reduction, n=3-8, p<0.05, Figure 22A and 22B).  Decrease of caspase-3 activity was also 
observed, (Figure 22C).  
 
 
 A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22– NaCl (0.5 mM) reduced the increase of caspase-3 levels and activity, induced by Aβ peptide. Cortical neurons 
were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated with 
NaCl (0.5 mM) and/or Aβ25-35 peptide (25 µM). In A, a representative Western blot of caspase-3 levels is provided. Histogram 
B shows mean ± SEM values of the ratio of caspase 3/ α-tubulin (One-way ANOVA test, *p<0.05, n=3-8). Histogram C shows 
mean ± SEM values of caspase-3 activity (One-way ANOVA test, *p<0.05, n=3-7). Dotted line represents the control values 
(CTR, no added drugs).  
 
 
In turn, a higher concentration of NaCl (10 mM) significantly reduced the expression of caspase-3 (77.7 ± 
8.1% reduction, n=3-8, p<0.05, Figure 23A and 23B) and its activity (76.3 ± 10.3% reduction, n=3-7, p<0.05, 
Figure 23C), induced by Aβ peptide. 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 – NaCl (10 mM) reduced, significantly, the increase of caspase-3 levels and activity, induced by Aβ peptide. 
Cortical neurons were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells 
were incubated either with NaCl (10 mM) and/or Aβ25-35 peptide (25µM). In A, a representative Western blot of caspase-3 
levels is provided. Histogram B shows mean ± SEM values of the ratio of caspase 3/ α-tubulin (One-way ANOVA test, *p<0.05, 
n=3-8). Histogram C shows mean ± SEM values of caspase-3 activity (One-way ANOVA test, *p<0.05, n=3-7). Dotted line 
represents the control values (CTR, no added drugs).  
 
 
4.3.3 – Effect of NaCl on TrkB receptor levels 
 
To evaluate if the decrease in the high expression levels and activity of caspase-3 induced by Aβ 
peptide observed upon incubation was related with TrkB receptor changes, as observed in LiCl experiments, 
both TrkB-FL and TrkB-Tc levels were studied.  
 NaCl alone, at 0.5, 10 or 50 mM concentrations, did not significantly change the levels of TrkB-FL or 
TrkB-Tc expression (n=3-6, Figures 24A and 24B). Consequently, the proportion between the two isoforms of the 
TrkB receptor did not change as well (Figure 24C), compared to control conditions.  
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d 
 
 
 
 
 
 
 
 
 
 
Figure 24 – TrkB receptor levels upon neuronal cultures incubation with NaCl. Cortical neurons were isolated and cultured 
for 7 days before incubation with drugs, as described in Methodologies. Cells were incubated with crescent concentrations of 
NaCl (0.5; 10 and 50 mM), for 24h. Histogram A shows mean ± SEM values of the ratio of TrkB-FL/ α-tubulin (One-way ANOVA 
test, p>0.05, n=3-6).  Histogram B shows mean ± SEM values of TrkB-Tc/ α-tubulin (One-way ANOVA test, p>0.05, n=3-6). 
Histogram C shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, p>0.05, n=3-6). Dotted 
line represents the control values (CTR, no added drugs).  
 
 
4.3.4 – Effect of NaCl on TrkB receptor levels upon incubation with Aβ peptide 
 
NaCl (0.5 mM), in the presence of Aβ peptide did not change, significantly, neither TrkB-FL nor TrkB-Tc 
receptor levels, when compared with samples incubated with Aβ peptide alone (n=6-10, Figure 25B and 25C). 
Although the differences were not significant, NaCl (0.5 mM) slightly increased the levels of the complete 
isoform and decrease the levels of the truncated isoform of TrkB receptor and therefore the TrkB-FL/TrkB-Tc 
ratio, in samples incubated simultaneously with Aβ peptide and NaCl (0.5 mM), were higher than in samples 
incubated with Aβ peptide alone (4.2 ± 1.22 fold, n=3-10, p<0.05, Figure 25D). 
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                          A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 – NaCl (0.5 mM) increased the TrkB-FL/TrkB-Tc ratio, in cortical neurons treated with Aβ peptide. Cortical 
neurons were isolated and cultured for 7 days before incubation with drugs, as described in Methodologies. Cells were 
incubated with NaCl (0.5 mM) and/or A25-35 peptide (25 M). In A, a representative Western blot of the levels of TrkB-FL and 
TrkB-Tc receptors is provided. Histogram B shows mean ± SEM values of the ratio of TrkB-FL/ α-tubulin (One-way ANOVA test, 
p>0.05, n=6-10). Histogram C shows mean ± SEM values of the ratio of TrkB-Tc/ α-tubulin (One-way ANOVA test, *p<0.05, 
n=6-10). Histogram D shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-way ANOVA test, *p<0.05, n=6-
10). Dotted line represents the control values (CTR, no added drugs).  
 
 
Incubation of neurons with NaCl (10 mM), in the presence of Aβ peptide, significantly increased TrkB-FL 
levels, when compared with levels of samples incubated with Aβ peptide alone (2.2 ± 0.3 fold, n=3-10, p<0.05, 
Figure 26B). This concentration of NaCl, however, was not able to induce a significant change in TrkB-Tc levels in 
neuronal cultures incubated with Aβ peptide (n=3-10, Figure 26C).  Analyzing the TrkB-FL/TrkB-Tc ratio, it is clear 
that NaCl (10 mM) was able to completely rescue the changes of TrkB levels induced by Aβ peptide bringing the 
proportion between the two isoforms to control values (p<0.05, Figure 26D). 
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                     A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 – NaCl (10 mM) changed TrkB-FL levels and increased the TrkB-FL/TrkB-Tc ratio, in cortical neurons treated with 
Aβ peptide. Cortical neurons were isolated and cultured for 7 days before incubation with drugs, as described in 
Methodologies. Cells were incubated with NaCl (10 mM) and/ or A25-35 peptide (25 M). In A, a representative Western blot 
of the levels of TrkB-FL and TrkB-Tc receptors is provided. Histogram B shows mean ± SEM values of the ratio of TrkB-FL/ α-
tubulin (One-way ANOVA test, *p<0.05, n=3-10). Histogram C shows mean ± SEM values of the ratio of TrkB-Tc/ α-tubulin 
(One-way ANOVA test, *p<0.05, n=3-10). Histogram D shows mean ± SEM values of the ratio of TrkB-FL/ TrkB-Tc levels (One-
way ANOVA test, *p<0.05, n=3-10). Dotted line represents the control values (CTR, no added drugs).  
 
 
Discussion 
 
To confirm if LiCl effects, described throughout this dissertation, were not merely a consequence of 
ionic changes, all the experiments performed with LiCl were reproduced with NaCl. The results obtained show 
that, despite some differences (Tables 5 and 6, Annex 1), incubation of neuronal cultures with this saline control 
was also able to reduce both the levels and the activity of caspase-3, as well as, reverse the changes in the levels 
of TrkB receptors induced by Aβ peptide. 
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Incubation of neuronal cultures with NaCl (0.5, 10 or 50 mM) alone, for 24 hours, did not significantly 
change neither caspase-3 levels nor its activity. On the other hand, administration of NaCl (0.5 or 10mM) to 
cultured neurons treated with Aβ peptide significantly reduced the high levels of caspase-3 caused by Aβ 
peptide. Regarding to caspase-3 activity induced by Aβ peptide, although both 0.5 mM and 10 mM 
concentrations of NaCl decreased this parameter, only the highest concentration was able to significantly 
decrease it.  
Following the reasoning up until now, the decrease observed in caspase-3 levels and its activity would 
suggest a neuroprotective action of NaCl against Aβ peptide-induced apoptosis. To clarify these results it is 
imperative to understand whether this reduction of the high levels and activity of caspase-3, induced by Aβ 
peptide, translates into a concomitant increase of cell viability. 
Regarding to TrkB receptor levels, NaCl (0.5 mM and 10 mM) was able to reverse the changes caused by 
Aβ peptide, increasing TrkB-FL/TrkB-Tc ratio, relatively to samples incubated with Aβ peptide alone, which 
suggests an improvement in BNDF/TrkB transducing signalling.  
The results described are in fact unexpected, and suggest that the neuroprotective effects of LiCl 
observed in this project as well as the numerous effects frequently assigned to lithium, may not be specific to 
this ion but instead a consequence of ionic changes.   
 
Protective effects of LiCl and NaCl against Aβ peptide toxicity, suggested by the decrease of caspase-3 
levels and activity, as well as, the reversion of TrkB receptor changes induced by Aβ peptide, may be a 
consequence of several phenomena. One hypothesis is that LiCl and NaCl are interfering with Aβ peptide, 
namely, with its state of aggregation. They could be somehow stabilizing Aβ peptide, avoiding its aggregation 
and, consequently, reducing its toxicity, which would translate in the prevention of apoptosis and TrkB changes. 
To verify this hypothesis, experiments to evaluate the state of aggregation of Aβ peptide, in the presence of NaCl 
and LiCl, are planned.  
The results obtained may also be a consequence of ionic changes. Administration of NaCl is particularly 
critical for neurons, since Cl
- 
and Na
+
 concentrations, in and out of the cells, are crucial for the maintenance of 
the membrane potential, especially in excitable cells. Currently, the relation between changes in ionic 
homeostasis and cell death remains unclear. However, studies have elucidated a novel role for changes in the 
intracellular milieu of the cells as important modulators of the cell death program. Intracellular ionic homeostasis 
has been, particularly, reported to be a determinant in both the activation and progression of the apoptotic 
cascade (Franco et al, 2006). Although, the lithium ion does not have a major role in the maintenance of 
membrane potential, it is able to enter in the cells throughout the sodium channels (Jancka and Jones, 1982). In 
the future, it is intended to explore this hypothesis by studying changes in ionic currents and in membrane 
potential, by patch clamp technique, upon administration of NaCl and LiCl to cells. 
In electrophysiological experiments it was demonstrated that BDNF actions, on hippocampal synaptic 
transmission, are facilitated by a depolarization caused by a K
+
 pulse (Diógenes et al, 2004), possibly by inducing 
the release of adenosine (Pazzagli et al, 1993). A similar mechanism might also be occurring upon incubation of 
neurons with NaCl and LiCl. As mentioned before, the ions that constitute these salts may change the membrane 
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potential. Perhaps, this action may improve BDNF signalling which would be, in the end, translated into 
neuroprotection against Aβ peptide-induced apoptosis. 
Since the effects of LiCl and NaCl, observed in this experimental work, may be a result of individual 
actions of chloride ion, some experiments with cesium chloride are also planned. 
In the future, we intend to explore all the possibilities mentioned to understand if the results obtained 
with NaCl and LiCl are independent or if LiCl neuroprotective actions are not specific of lithium but rather a 
consequence of ionic changes.     
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5| Conclusions 
 
First of all, in this experimental project, the possibility of LiCl acting to protect neuronal cultures from 
apoptotic cell death induced by Aβ peptide was studied. Incubation of cultured neurons with LiCl (10 mM), for 
24 hours, reduced the high levels and activity of caspase-3, observed upon Aβ25-35 peptide (25 µM) 
administration. 
    
In the second objective of this work, the possible mechanisms that could be underlying neuroprotective 
effects of LiCl against Aβ peptide were explored.  
Several studies suggest a strong relation between lithium and BDNF/TrkB pathway, reporting that 
lithium increases the levels of endogenous BDNF and the phosphorylation of TrkB receptors. Moreover the 
neuroprotective effects of BDNF against Aβ peptide were already shown. Since the levels of this neurotrophin 
and TrkB receptors are changed in the brain of AD patients and a decrease of TrkB-FL isoform accompanied by an 
increase of TrkB-Tc receptors were correlated with the presence of Aβ peptide, in this project the possibility of 
whether LiCl could reverse changes in TrkB receptor levels, induced by Aβ peptide was studied. The results 
obtained revealed that LiCl (10 mM) was able to rescue the changes in the TrkB receptor levels induced by Aβ 
peptide, increasing significantly the TrkB-FL isoform, which is associated with the neuroprotective effects of 
BDNF.  Therefore, the data obtained support the hypothesis that neuroprotective actions of LiCl against Aβ 
peptide could be mediated by BDNF/TrkB pathway.  
 
Lithium is frequently described as an inducer of autophagy, a process associated with cell survival which 
has been suggested to counteract apoptosis and neutralize damaged areas in the brain by isolating activated 
caspase-3 into autophagic vacuoles. For that reason, it was also studied the potential involvement of autophagy 
in LiCl effects. Preliminary data obtained in PC12 cell line, suggests that LiCl (10 mM) is, in fact, able to induce 
autophagy. Considering that LiCl is also able to induce this process on neurons, the results obtained upon 
incubation of neuronal cultures with 3-MA, an autophagic inhibitor, suggest that autophagy does not mediate 
the neuroprotective effects of LiCl against Aβ peptide-induced apoptosis.  
 
To verify whether LiCl effects on caspase-3 levels and activity, as well as, on TrkB receptor levels, were a 
consequence of ionic changes, all the experiments were reproduced with NaCl. The results obtained were 
unexpected and showed that this saline control was also able to reduce the high levels and activity of caspase-
3, induced by Aβ peptide. In addition, NaCl revert the changes, induced by Aβ peptide, in the levels of TrkB 
receptors.  
  
In conclusion, this experimental work showed that LiCl prevents apoptosis and the changes in TrkB 
receptor levels, induced by Aβ peptide. However, since these effects were also achieved by incubating neuronal 
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cultures with its saline control, NaCl, which the vast majority of published works do not test, this work suggests 
that many of neuroprotective effects associated with lithium might be related with ionic changes.   
 
. 
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7| Annex I 
 
Table 5 – Main effects of LiCl or NaCl on caspase-3 levels and activity, relatively to neuronal cultures 
incubated with Aβ peptide alone 
Effects on caspase-3 levels and activity upon incubation with Aβ peptide 
LiCl (0.5 mM) 
The decrease of the high levels and activity of caspase-3, induced by Aβ peptide, was not 
significant 
LiCl (10 mM) 
Decreased significantly both levels and activity of caspase-3, induced by Aβ peptide (71.3 
± 11.1% and 48.8 ± 8.4%, respectively) 
NaCl (0.5 mM) 
Decreased both levels and activity of caspase-3, induced by Aβ peptide, reducing 
significantly the first parameter (77.4 ± 9.0%) 
NaCl (10 mM) 
Decreased significantly both levels and activity of caspase-3, induced by Aβ peptide (77.7 
± 8.1% and 76.3 ± 10.3%, respectively) 
 
 
Table 6 – Main effects of LiCl or NaCl on TrkB receptor levels, relatively to neuronal cultures incubated 
with Aβ peptide alone 
Effects on TrkB receptor levels upon incubation with Aβ peptide 
LiCl (0.5 mM) Did not revert the changes in TrkB receptor levels induced by Aβ peptide 
LiCl (10 mM) 
Prevented the decrease of TrkB-FL levels, induced by Aβ peptide and kept the TrkB-
FL:TrkB-Tc proportion at control values 
NaCl (0.5 mM) 
Although individual changes in TrkB receptor levels were not significant, the increase of 
TrkB-FL and decrease of TrkB-Tc receptors  prevented the reduction  of TrkB-FL/TrkB-Tc 
ratio induced by Aβ peptide 
NaCl (10 mM) Prevented TrkB-FL decreased, and kept the TrkB-FL:TrkB-Tc proportion at control values 
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